CSLCarlisle Companies Inc.
Company Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
Dividends Predicted
Dec 2, 2026
$1.25 per share
Sentiment
Score
Bullish
61
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Other Operating Expenses / (Income)
Total Operating Expenses
Interest Expense
Interest & Investment Income
Earnings History
- Estimated
- Reported, beat
- Reported, missed
Estimated EPS
Reported EPS
N/ACompany Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
Dividends Predicted
Dec 2, 2026
$1.25 per share
Sentiment
Score
Bullish
61
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Other Operating Expenses / (Income)
Total Operating Expenses
Interest Expense
Interest & Investment Income
Earnings History
- Estimated
- Reported, beat
- Reported, missed
Estimated EPS
Reported EPS
N/AUpcoming Earnings
Company Info
CEO
David C. Koch
Location
Arizona, USA
Exchange
NYSE
Website
https://carlisle.com
Summary
Carlisle Companies Incorporated operates as a diversified manufacturer of engineered products.
Company Info
CEO
David C. Koch
Location
Arizona, USA
Exchange
NYSE
Website
https://carlisle.com
Summary
Carlisle Companies Incorporated operates as a diversified manufacturer of engineered products.
Community Research
Research from investors like you
Be the first to share your analysis on CSL
Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.
Symbol's posts
Is This Partnership a Smart Move?
Is This Partnership a Smart Move?
announced a global partnership with Alentis Therapeutics. The partnership will focus on lixudebart. Lixudebart is being studied for rare kidney and liver diseases. The company wants to add new treatment options beyond its main products. Rare diseases can have high unmet need. That can also mean strong pricing power if a treatment works. The company still needs to prove the drug is safe and effective. I like the idea, but I want to see clinical progress before I get excited about the update
No more topics to show
